Following the acquisition of Molecular Response and the appointment of a new Senior Vice President Global Strategy, this announcement is a crucial development in Crown’s global expansion strategy and promises to considerably strengthen the company’s position within the European drug discovery market.
Dempe has over eight years of experience working within the oncology research community, with extensive knowledge of in vitro and in vivo studies of human pancreatic adenocarcinomas, as well as virotherapy of cancer using natural and armed oncolytic parvoviruses, strengthening anticancer immune responses. With more than three years as Business Development Manager for ProQinase, Dempe specializes in promoting recombinant kinases as well as R&D services, and has developed a substantial network of industry contacts within Germany and wider Europe. As Crown’s BD manager based in Germany, he will continue to engage with drug developers primarily based in Germany, Switzerland and Austria, as part of Crown’s growing European network of BD managers providing local support for European clients across Europe.
“Sebastian is a welcome addition to the team, bringing with him a wealth of experience working within a key geography for drug discovery” comments Laurie Heilmann, recently appointed Senior Vice President Global Strategy of Crown Bioscience Inc. “As part of our ambitious growth strategy, his considerable knowledge of the industry, coupled with his influence in the local drug discovery community, will provide us with a considerable advantage in strengthening our existing operations and leveraging our position within the European market.”
The appointment of Mr Dempe, follows several high profile announcements made in the first quarter of 2015. With the recent acquisition of Molecular Response, Crown has the largest and most comprehensive collection of clinically and ethnically diverse patient derived xenograft (PDX) models in the world. In February, Crown also announced the expansion of its partnership with the National Resource Center for Mutant Mice to develop novel immuno-oncology mouse models for use in immunotherapy research. With new appointments in key geographies Crown is now moving to establish global access to its superior service platforms and reinforce its commitment to assisting drug development companies reduce cancer to a manageable chronic disease.